Alzheimer’s Drugs: UK Cost-Effectiveness Ruling
- LONDON — The national Health Service (NHS) in the United Kingdom will not make two new Alzheimer's drugs available, as a U.K.
- Eli Lilly’s kisunla (donanemab) and Biogen and Eisai’s Leqembi (lecanemab) had previously received approval from U.K.
- The decision reflects a broader trend of health authorities grappling with the balance between innovative treatments and sustainable healthcare spending.
UK health authorities have rejected two new Alzheimer’s drugs due to their high costs, a move impacting access to vital treatments. The NHS will not cover kisunla and Leqembi,despite prior approval from regulators. This decision underscores the crucial debate on balancing innovative treatments and sustainable healthcare spending, reflecting limited benefits versus their price point. While approved, the U.K. health agency deemed the medications not cost-effective. This follows global discussions on Alzheimer’s treatment pricing. Discover the latest developments in this critical healthcare discussion at News Directory 3. The future of these drugs in the UK remains uncertain; keep up-to-date. Discover what’s next…
UK Health Agency Rejects Alzheimer’s Drugs Over High Costs
LONDON — The national Health Service (NHS) in the United Kingdom will not make two new Alzheimer’s drugs available, as a U.K. health agency has steadfast their limited benefits do not justify their high prices. This decision highlights the ongoing global debate surrounding the cost-effectiveness of new treatments for Alzheimer’s disease.
Eli Lilly’s kisunla (donanemab) and Biogen and Eisai’s Leqembi (lecanemab) had previously received approval from U.K. regulators. The Medicines and Healthcare products Regulatory Agency concluded that the benefits of these Alzheimer’s treatments outweighed the risks for specific patient groups.
What’s next
The decision reflects a broader trend of health authorities grappling with the balance between innovative treatments and sustainable healthcare spending. The future availability of these Alzheimer’s drugs in the UK remains uncertain pending further developments.